Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in children. It is a genetic disorder characterized by progressive muscle degeneration and weakness and is one of nine types of muscular dystrophy.
The clinical hallmarks of DMD include weakness and wasting of various voluntary muscles of the body. In the most advanced stages of the disease, the heart and gut muscles will be affected. Symptoms of DMD are usually noticed in boys between 1–6 years. Also, a steady decline occurs in muscle strength between the ages of 6–11. By age 10, braces may be needed for walking, and by age 13, most boys with DMD are using a wheelchair full-time.
Children with DMD are often late walkers. In toddlers, parents may notice enlarged calf muscles. This enlargement is known as pseudohypertrophy, or “false enlargement” because the muscle tissue is abnormal and may contain scar tissue. A preschooler with DMD may seem clumsy and fall often. Parents also may note that children have trouble climbing stairs, getting up from the floor, or running.
Get FREE sample copy at:
The Duchenne Muscular Dystrophy market report also covers emerging drugs, current treatment practices, Duchenne Muscular Dystrophy market share of the individual therapies, current and forecasted Duchenne Muscular Dystrophy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Duchenne Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Duchenne Muscular Dystrophy Market Key Facts
The total diagnosed prevalent population of Duchenne Muscular Dystrophy in the 7 major markets was 27,685 in 2017, whereas the diagnosed prevalent cases of Duchenne Muscular Dystrophy patients in the United States were 16,840.
DMD can be caused by around 2,000 mutations in the Duchenne Muscular Dystrophy gene. The Duchenne Muscular Dystrophy gene is the largest known gene in humans, spanning 2.3 Mb of genomic DNA. In the United States, The number of patients with large mutations was found to be 13,472 in 2017.
The maximum number of total diagnosed prevalent cases of Duchenne Muscular Dystrophy patients were found in the age group 8–13 and 14–19 in the United States, which were 4,757 and 4,714 cases, respectively, in 2017.
In the United States, the diagnosed prevalence of associated comorbidities in Duchenne Muscular Dystrophy was found to be maximum in the case of Scoliosis, which was 3,368 in 2017.
In EU5 countries, the diagnosed prevalence of Duchenne Muscular Dystrophy was found to be 8,617 in 2017, which is expected to rise in the forecast period 2020–2030.
Key Benefits of Duchenne Muscular Dystrophy Market Report
Duchenne Muscular Dystrophy market report provides an in-depth analysis of Duchenne Muscular Dystrophy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Duchenne Muscular Dystrophy market report will help in developing business strategies by understanding the Duchenne Muscular Dystrophy Market trends & developments, key players and future market competition that will shape and drive the Duchenne Muscular Dystrophy market in the upcoming years.
The Duchenne Muscular Dystrophy market report covers Duchenne Muscular Dystrophy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Duchenne Muscular Dystrophy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in 7Mm.
The Duchenne Muscular Dystrophy market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Duchenne Muscular Dystrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Duchenne Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Duchenne Muscular Dystrophy Epidemiology
The Duchenne Muscular Dystrophy epidemiology section covers insights about historical and current Duchenne Muscular Dystrophy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Duchenne Muscular Dystrophy Drugs Uptake and Key Market Players
The Duchenne Muscular Dystrophy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched in the market during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key companies in the Duchenne Muscular Dystrophy market include:
Duchenne Muscular Dystrophy Therapies Covered:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis
4. Duchenne Muscular Dystrophy Market Overview at a Glance
5. Duchenne Muscular Dystrophy Disease Background and Overview
6. Duchenne Muscular Dystrophy Patient Journey
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Duchenne Muscular Dystrophy Unmet Needs
10. Key Endpoints of Duchenne Muscular Dystrophy Treatment
11. Duchenne Muscular Dystrophy Marketed Products
12. Duchenne Muscular Dystrophy Emerging Therapies
13. Duchenne Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Duchenne Muscular Dystrophy Market Outlook (7 major markets)
16. Duchenne Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Duchenne Muscular Dystrophy Market.
18. Duchenne Muscular Dystrophy Market Drivers
19. Duchenne Muscular Dystrophy Market Barriers
21. DelveInsight Capabilities
Duchenne Muscular Dystrophy Epidemiology Forecast
DelveInsight’s Duchenne Muscular Dystrophy – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of DMD in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Duchenne Muscular Dystrophy Pipeline Insights
Duchenne Muscular Dystrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Duchenne Muscular Dystrophy market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States